Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: jerusalem g. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S. Capri G, et al. Among authors: jerusalem g. Ann Oncol. 2010 Mar;21(3):474-480. doi: 10.1093/annonc/mdp373. Epub 2009 Oct 8. Ann Oncol. 2010. PMID: 19815649 Free article. Clinical Trial.
[Breast cancer and brain metastases].
Rorive A, Collignon J, Martin M, André C, Jerusalem G, Coucke P. Rorive A, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):299-305. Rev Med Liege. 2011. PMID: 21826966 Free article. French.
[Hormone therapy for breast cancer].
Lifrange E, Andre C, Bleret V, Collignon J, Coucke P, Cusumano P, Desreux J, Herman P, Jerusalem G, Kridelka F, Martin M, Rorive A, Van Cauwenberge JR, Colin C. Lifrange E, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):367-71. Rev Med Liege. 2011. PMID: 21826978 Free article. French.
[Systemic chemotherapy and breast cancer].
Collignon J, Rorive A, Martin M, Andre C, Maweja S, Lifrange E, Coucke P, Jerusalem G. Collignon J, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):372-8. Rev Med Liege. 2011. PMID: 21826979 Free article. French.
[Breast cancer in young women].
André C, Collignon J, Rorive A, Martin M, Maweja S, Lifrange E, Coucke P, Jerusalem G. André C, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):397-9. Rev Med Liege. 2011. PMID: 21826983 Free article. French.
[Breast cancer in the elderly patient].
Martin M, Collignon J, Rorive A, André C, Bourhaba M, Allepaerts S, Coucke P, Lifrange E, Jerusalem G. Martin M, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):400-8. Rev Med Liege. 2011. PMID: 21826984 Free article. French.
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Garnett SA, Martin M, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Lindemann JP, Di Leo A. Garnett SA, et al. Among authors: jerusalem g. Breast Cancer Res Treat. 2013 Feb;138(1):149-55. doi: 10.1007/s10549-012-2395-8. Epub 2013 Feb 3. Breast Cancer Res Treat. 2013. PMID: 23378064 Free PMC article. Clinical Trial.
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M. Di Leo A, et al. Among authors: jerusalem g. J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7. J Natl Cancer Inst. 2014. PMID: 24317176 Free PMC article. Clinical Trial.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. André F, et al. Among authors: jerusalem g. Lancet Oncol. 2014 May;15(6):580-91. doi: 10.1016/S1470-2045(14)70138-X. Epub 2014 Apr 14. Lancet Oncol. 2014. PMID: 24742739 Clinical Trial.
278 results